Vascular Dysfunction in Leukoaraiosis

K. Sam, A.P. Crawley, J. Poubioncé, J. Conklin, O. Sobczyk, D.M. Mandell, J. Duffin, L. Venkatraghavan, J.A. Fisher, S.E. Black and D.J. Mikulis

AJNR Am J Neuroradiol 2016, 37 (12) 2258-2264
doi: https://doi.org/10.3174/ajnr.A4888
http://www.ajnr.org/content/37/12/2258
Vascular Dysfunction in Leukoaraiosis

K. Sam, A.P. Crawley, J. Poublanc, J. Conklin, O. Sobczyk, D.M. Mandell, J. Duffin, L. Venkatraghavan, J.A. Fisher, S.E. Black, and D.J. Mikulis

ABSTRACT

BACKGROUND AND PURPOSE: The pathogenesis of leukoaraiosis has long been debated. This work addresses a less well-studied mechanism, cerebrovascular reactivity, which could play a leading role in the pathogenesis of this disease. Our aim was to evaluate blood flow dysregulation and its relation to leukoaraiosis.

MATERIALS AND METHODS: Cerebrovascular reactivity, the change in the blood oxygen level–dependent 3T MR imaging signal in response to a consistently applied step change in the arterial partial pressure of carbon dioxide, was measured in white matter hyperintensities and their contralateral spatially homologous normal-appearing white matter in 75 older subjects (age range, 50–91 years; 40 men) with leukoaraiosis. Additional quantitative evaluation of regions of leukoaraiosis was performed by using diffusion (n = 75), quantitative T2 (n = 54), and DSC perfusion MRI metrics (n = 25).

RESULTS: When we compared white matter hyperintensities with contralateral normal-appearing white matter, cerebrovascular reactivity was lower by a mean of 61.2% ± 22.6%, fractional anisotropy was lower by 44.9% ± 6.9%, and CBF was lower by 10.9% ± 11.9%. T2 was higher by 61.7% ± 13.5%, mean diffusivity was higher by 59.0% ± 11.7%, time-to-maximum was higher by 44.4% ± 30.4%, and TTP was higher by 6.8% ± 5.8% (all P < .01). Cerebral blood volume was lower in white matter hyperintensities compared with contralateral normal-appearing white matter by 10.2% ± 15.0% (P = .03).

CONCLUSIONS: Not only were resting blood flow metrics abnormal in leukoaraiosis but there is also evidence of reduced cerebrovascular reactivity in these areas. Studies have shown that reduced cerebrovascular reactivity is more sensitive than resting blood flow parameters for assessing vascular insufficiency. Future work is needed to examine the sensitivity of resting-versus-dynamic blood flow measures for investigating the pathogenesis of leukoaraiosis.

ABBREVIATIONS: BOLD = blood oxygen level–dependent; CVR = cerebrovascular reactivity; MD = mean diffusivity; NAWM = normal-appearing white matter; PaCO2, PaO2 = end-tidal partial pressure of carbon dioxide; PETCO2 = end-tidal partial pressure of oxygen; WMH = white matter hyperintensities

Age-related changes in the cerebral white matter are apparent on MR imaging. They appear as bright regions on T2-weighted images and are called white matter hyperintensities (WMH) if they are presumed to be of vascular origin. These areas are characterized by myelin pallor, reactive astrogliosis, and loss of oligodendrocytes, axons, and myelin fibers. This rarefaction of white matter tissue is the origin of the term “leukoaraiosis,” derived from the Greek words “leuko-” for white and “araios” for rarefied. As many as 95% of individuals older than 50 years of age demonstrate these white matter changes, particularly in the periventricular and deep white matter. Once thought to represent benign age-related changes, studies during the past 25 years have shown that WMH are associated with morbidity, including cognitive impairment and disability. Substantial evidence indicates that age-related vascular changes may lead to WMH, including increased vessel tortuosity.
increased stringed vessels (remnants of capillaries with no endothelial cells), and vessel basement membrane thickening.\textsuperscript{10} Histopathologic analysis of abnormal white matter shows venular intramural collagen deposition leading to wall-thickening stenosis.\textsuperscript{11} The vascular anatomy of the white matter provides an intrinsically higher vascular resistance compared with the cortex.\textsuperscript{12} Interestingly, white matter areas with excellent collateral blood supply, such as the subcortical U-fibers, do not usually show age-related WMH.\textsuperscript{13} Collectively, these findings suggest an association between vascular dysfunction and leukoaraiosis.

In the present study, we sought to further characterize the vascular pathophysiology of WMH by evaluating cerebrovascular reactivity (CVR). CVR is defined as the change in cerebral blood flow induced by a vasoactive stimulus. Reduced CVR, normally found in the white matter of young healthy individuals,\textsuperscript{14} has been shown to spatially correspond with predilection maps of age-related leukoaraiosis development.\textsuperscript{15} CVR reductions are associated with cortical thinning,\textsuperscript{16} the risk of future ischemic stroke,\textsuperscript{17} cognitive decline,\textsuperscript{18} and abnormal diffusion tensor imaging metrics.\textsuperscript{19} WMH are associated with increased mean diffusivity (MD) and decreased fractional anisotropy, likely representing axonal destruction and glial proliferation.\textsuperscript{20} Previous studies have found a relationship between impaired CVR and abnormal diffusion metrics in the white matter of patients with Moyamoya disease\textsuperscript{21} and steno-occlusive carotid disease,\textsuperscript{21} suggesting that chronic hypoperfusion is associated with pathologic changes to white matter microstructure. Moreover, vascular dysfunction in the form of blood-brain barrier leakage in WMH is also associated with increased MD.\textsuperscript{22}

We evaluated CVR in regions of WMH and normal-appearing white matter (NAWM) by measuring the change in blood oxygen level–dependent (BOLD) MR imaging in response to a standard CO\textsubscript{2} challenge. To characterize the hemodynamic properties and microstructure of WMH, we obtained additional MR images and performed DTI and DSC perfusion MR imaging. We hypothesized that both CVR and these additional MR imaging metrics would differ between leukoaraiosis and NAWM.

**MATERIALS AND METHODS**

**Subject Recruitment**

Seventy-five older adults with age-related leukoaraiosis (age range, 50–91 years; 40 men) were recruited from outpatient neurology clinics at the Toronto Western Hospital and Sunnybrook Health Sciences Centre. Reasons for clinical referral included the following: chronic imbalance, gait disturbances, transient episodes of paresthesia, syncopal episodes, headaches, cognitive decline, or memory impairment. Informed consent and institutional research ethics board approval were obtained. All patients had undergone prior MRA or CTA and T2-weighted FLAIR imaging, which were screened by experienced neuroradiologists (D.M.M. and D.J.M.) before inclusion in the study.

Because no direct histologic confirmation could be obtained, the diagnosis of leukoaraiosis was based on the exclusion of other diseases that can generate MR imaging T2-weighted hyperintensities (subsequently listed). Clinical and imaging-based inclusion criteria were as follows: 1) a previous neurologic event involving the white matter >3 months from presentation; 2) older than 50 years of age; 3) MRI white matter disease burden greater than Fazekas grade 2\textsuperscript{3,24}; 4) no hemodynamically significant (ie, >50%) stenosis of the ICAs, vertebral arteries, or basilar artery on CTA or MRA; 5) no evidence of dissection; 6) no evidence of pulmonary or cardioembolic disease; and 7) no known history of CADASIL, multiple sclerosis, primary malignancy, previous CNS infection, or head trauma. Subjects with significant motion artifacts on BOLD images were excluded.

Forty-three patients from the Toronto Western Hospital (age range, 50–87 years; 23 men and 20 women), and 32 patients from Sunnybrook Health Sciences Centre (age range, 51–91 years; 17 men and 15 women) met the inclusion criteria and were considered in subsequent analysis. Age, Montreal Cognitive Assessment score,\textsuperscript{22} gray matter volume, and white matter volume were collected as continuous variables. History of stroke, TIA, coronary artery disease, smoking, hypertension, diabetes mellitus, dyslipidemia, hypercholesterolemia, and obstructive sleep apnea were collected as binary variables.

**MR Imaging Acquisition**

Subjects underwent MR imaging on a 3T system (Signa HDx platform; GE Healthcare, Milwaukee, Wisconsin) at the Toronto Western Hospital and a 3T Achieva system (Philips Healthcare, Best, the Netherlands) at Sunnybrook Health Sciences Centre by using an 8-channel phased array head coil. Subjects were asked to refrain from heavy exercise and drinking alcohol on the day of each scan. The imaging acquisition parameters were as follows:

- **T1-weighted 3D spoiled gradient-echo sequence:** section thickness = 1.2–1.5 mm, matrix size = 256 × 256, FOV = 22 × 22 cm, flip angle = 8° to 20°, TE = 2.3–3 ms, TR = 7.8–9.5 ms; BOLD sequence was a T2*-weighted echo-planar imaging gradient-echo sequence: section thickness = 3.0–5.0 mm, FOV = 24 × 24 cm, matrix size = 64 × 64, flip angle = 85° to 90°, TE = 30 ms, TR = 2000 ms; conventional FLAIR images: section thickness = 3 mm, 36 to 52 sections per volume, no intersection gap, matrix size = 256 × 224 to 240 × 240, FOV = 22 × 22 cm, flip angle = 90°, TE = 125 to 165 ms, TR = 9000 to 9145 ms, TI = 2200 to 2800 ms; diffusion tensor imaging with an echo-planar imaging spin-echo sequence: section thickness = 3 mm, matrix size = 76 × 62 to 128 × 128, FOV = 22 × 22 cm, b = 1000 s/mm\textsuperscript{2}, 23 diffusion-encoding gradients, 2 non-diffusion-weighted B0 images, TE = 55–80 ms, TR = 9150–14,500 ms; proton-density/T2-weighted images using fast spin-echo: section thickness = 3 mm, matrix size = 128 × 128 to 256 × 209, FOV = 22 × 22 cm, flip angle = 90°, TE = 11.1/90–11/102 ms, TR = 2500–7200 ms; multiecho T2 mapping using a fast spin-echo: section thickness = 3 mm, no intersection gap, matrix size = 256 × 192, FOV = 230 × 184 to 22 × 22 cm, TE = 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156 ms, TR = 5000–6000 ms; and DSC perfusion imaging using a gradient-multiphase-echo echo-planar imaging sequence: section thickness = 5 mm, matrix size = 128 × 128, FOV = 27 × 27 cm, flip angle = 90°, TE = 31.5 ms, TR = 1725 ms, 50 sections per location, during which a single bolus of 0.1 mmol/kg of gadolinium contrast agent was injected at a rate of 5 mL/s.
**Vasodilatory Stimulus**

CVR was assessed by measuring the change in BOLD MR imaging in response to a standardized change in end-tidal (ie, end-expiratory) partial pressure of carbon dioxide (P_{ET}\text{CO}_2) as the vasodilatory stimulus.\textsuperscript{25} P_{ET}\text{CO}_2 and end-tidal partial pressure of oxygen (P_{ET}\text{O}_2) were targeted independently of each other and of the subjects’ minute ventilation and breathing pattern by using an automated gas blander and sequential gas delivery breathing circuit (RespirAct; Thornhill Research, Toronto, Canada). Targeting P_{ET}\text{CO}_2 and P_{ET}\text{O}_2 was achieved by administering blends of gases according to previously described algorithms.\textsuperscript{26} The targeting sequence used in this study was the following: 1) baseline P_{ET}\text{CO}_2 of 40 mm Hg for 60 seconds (normocapnia); 2) hypercapnic step change to P_{ET}\text{CO}_2 of 50 mm Hg for 90 seconds; 3) return to baseline for 90 seconds; and 4) a second hypercapnic step for 120 seconds with a final return to baseline.\textsuperscript{27} All steps were implemented while maintaining normoxia (P_{ET}\text{O}_2 ~ 110 mm Hg). CVR was calculated as Δ% BOLD/P_{ET}\text{CO}_2. CVR maps were displayed on a blue-to-red color scale, with regions of negative CVR (representative of steal physiology) in blue.

**Image Reconstruction**

The acquired BOLD MR imaging and P_{ET}\text{CO}_2 data were imported to a freeware program for analysis, Analysis of Functional Neuro Images (AFNI; http://afni.nimh.nih.gov/afni). The BOLD time-series at each voxel was orthogonalized to 6 translational and rotational rigid body motion estimates by using the AFNI volume registration procedure to minimize any influence of hypercapnia-related head motion. BOLD images were section time-corrected and aligned to axial anatomic T1-weighted images. T1- and T2-weighted images were reviewed to identify regions of parenchymal infarction and prior hemorrhage. Masks of each parenchymal lesion were manually traced in AFNI and excluded from the CVR maps, which were calculated according to previously validated methods.\textsuperscript{29} T1-weighted anatomic images were segmented into CSF, gray matter, and white matter by using SPM8 software (http://www.fil.ion.ucl.ac.uk/spm/). CSF was masked from the CVR maps.

Maps of the traverse relaxation time (T2) were calculated to confirm tissue dysfunction in the cerebral white matter. T2 reflects white matter water content and myelination and was calculated in AFNI by using methods previously described.\textsuperscript{30} To calculate fractional anisotropy and MD maps, we imported diffusion-weighted images into FSL 4.1.8 (http://www.fmrib.ox.ac.uk/fsl).\textsuperscript{31} Preprocessing included eddy current and motion artifact correction by using the FMRIB Diffusion Toolbox (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT).\textsuperscript{32} Individual brain masks were created by using the FSL Brain Extraction Tool (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/BET).\textsuperscript{33} The preprocessed images were then fitted with a diffusion tensor model by using DTIFit (http://fsl.fmrib.ox.ac.uk/fsl/4.1.9/fdt/fdt_difit.html),\textsuperscript{31} and parametric maps of fractional anisotropy and MD were calculated for each subject.

The time-signal attenuation curves obtained from perfusion-weighted T2* images were converted to time-concentration curves by using PerfTool,\textsuperscript{34} which uses a delay-insensitive reformulated singular value decomposition approach to deconvolution of the time-concentration curves.\textsuperscript{35} The arterial input function was selected from an ROI placed on the middle cerebral artery. These preprocessed perfusion-weighted images were used to generate maps of cerebral blood flow, relative cerebral blood volume, mean transit time, time-to-maximum, and time-to-peak by using PerfTool.\textsuperscript{34}

**Generating CVR Maps**

P_{ET}\text{CO}_2 data were first synchronized to the whole-brain average BOLD signal by using Matlab software (MathWorks, Natick, Massachusetts) to compensate for delays in breath sample analysis and the transit delay of blood flow from the pulmonary to cerebral circulation. A voxel-by-voxel linear least-squares fit of the BOLD signal time-series to the P_{ET}\text{CO}_2 was performed, and the slope of the regression was taken as the CVR. CVR values are expressed as the percentage MR signal change per millimeter of mercury of P_{ET}\text{CO}_2.

**Generating ROIs of WMH and NAWM**

The Lesion Explorer processing pipeline (available for download at http://sabre.brainlab.ca) was used to segment WMH and obtain measures of supratentorial total intracranial volume (total brain tissue and CSF).\textsuperscript{36,37} All T1-weighted images were transformed into Montreal Neurological Institute space by using SPM8. The transformation matrix was applied to all quantitative MR imaging maps to perform the transformation to standard space while retaining the native structure. AFNI was used to identify NAWM contralateral to WMH. In brief, a diamond-shaped structuring element was used to erode the white matter in 5 iterations at the resolution of the T1-weighted image to prevent partial voluming effects. The WMHs were subtracted after erosion to give rise to a NAWM mask contralateral to the WMH ROI.

**Accounting for the Confounding Factor of Spatial Location**

One important confounding factor that may produce differences between WMH and NAWM is spatial location. For example, WMH tend to develop in the periventricular white matter, and CVR may be lower in these areas. Therefore, CVR measurements in NAWM may be overestimated because CVR values in these regions tend to be higher. To account for this possibility, a second NAWM ROI was generated, including only those NAWM regions that are contralateral and spatially homologous to the regions of WMH (Fig 1).

**Statistical Analyses**

Statistical analysis was performed with SPSS 21.0 (IBM, Armonk, New York). To assess the relationship between CVR and cognitive function, we performed a univariate general linear regression between CVR (within NAWM or WMH) and Montreal Cognitive Assessment scores, while controlling for age, sex, vascular risk factors, and total gray and white matter volume.

The relationship between each vascular risk factor and CVR was assessed with univariate regression analyses by using the CVR within each ROI (namely, WMH or NAWM, Fig 1G) as the dependent variable and either age, sex, Montreal Cognitive Assessment score, vascular risk factors (listed in Table 1), total gray
matter volume, WMH volume, or NAWM volume as the independent variable. Partial $\eta^2$ effect sizes were calculated for significant between-group results (ie, the presence-versus-absence of each vascular risk factor).

To assess the relationship between CVR, diffusion, and perfusion metrics, we calculated the Pearson linear correlation coefficient for each comparison between metrics, by using the difference in each parameter value between WMH and NAWM.

Statistical comparisons of CVR, DTI, and perfusion parameter differences between WMH and NAWM were performed by using a paired Student $t$ test. Results were considered significant at $\alpha = .05$.

RESULTS

The 75 subjects had a mean WMH volume of 26.7 $\pm$ 23.5 mL per subject (range, 0.3–93.9 mL). Table 1 provides their demographics. Table 2 shows comparisons between WMH and the contralateral NAWM. Comparisons between these 2 ROIs for each metric are provided in Fig 2.

CVR, fractional anisotropy, and CBF were reduced in WMH compared with NAWM, while T2, MD, and time-to-maximum were increased in WMH compared with NAWM (all, $P < .01$). CBV was reduced in WMH compared with NAWM ($P = .03$). MTT values were not significantly different between WMH and NAWM. There was no correlation between CVR and the other diffusion and perfusion metrics for any of the ROIs considered (WMH, NAWM, and total white matter); and there was no relationship between CVR and Montreal Cognitive Assessment scores (mean, 24/30 $\pm$ 4.8). Previous stroke was associated with lower CVR in WMH ($P < .05$; $\eta^2 = 0.07$ moderate effect size). There was no significant association between CVR and the remaining vascular risk factors listed in Table 1.

DISCUSSION

Our results provide evidence for vascular dysfunction in regions of leukoaraiosis, characterized by quantitative changes in multiple MR imaging parameters. Compared with the contralateral NAWM, the increased MD and decreased fractional anisotropy in leukoaraiosis are consistent with the findings in previous studies and indicate that white matter structural integrity has been compromised and water is able to diffuse more freely through areas of demyelination and axonal degeneration. Quantitative T2 values were higher in leukoaraiosis, which is to be expected because this indicates increased water content due to loss in tissue structure. CBF was reduced; this change indicated a reduction in blood supply; CBV was also reduced; this change suggested decreased density of the local microvasculature. Finally, time-dependent MR imaging metrics such as time-to-maximum and TTP were prolonged in leukoaraiosis; this finding demonstrates a delay in the blood supply to areas of leukoaraiosis. Collectively, these abnormal MR imaging metrics provide evidence for vascular dysfunction in areas of leukoaraiosis in our cohort of patients.

We also found that CVR in regions of leukoaraiosis was significantly lower than in NAWM. These results are similar to findings from a previous study by Uh et al reporting lower CVR values in leukoaraiosis. However, the approach to CVR quantification in the present study is more accurate. Inhalation of 5% CO2 (as performed by Uh et al) produces a variable PaCO2 stimulus that depends on the subject’s minute ventilation and breathing pattern, which can lead to inaccurate CVR quantitation. Our ability to maintain a standardized extended period of hypercapnia (independent of minute ventilation) provides greater confidence in the accuracy of our CVR measurements.

Reduced CVR suggests a role for endothelial dysfunction in the development of leukoaraiosis and is consistent with the findings of Hassan et al, who demonstrated upregulated markers of endothelial activation and damage in leukoaraiosis. By account-
NAWM. These observations of reduced perfusion metrics and CVR in leukoaraiosis are also in agreement with predition maps demonstrating that regions of white matter with lower perfusion have a higher frequency of leukoaraiosis. Finally, we found prolonged time-dependent perfusion measures in leukoaraiosis. Prolonged TTP and time-to-maximum values have also been reported in the infarct core of patients with acute stroke, by using CT perfusion.

CVR may be more sensitive than resting blood flow metrics for the following reasons: CBF measures can be normal due to the action of vascular autoregulation, CBV is difficult to quantitate accurately, and transit time measures can be increased but with normal CVR, with collaterals that maintain normal resting blood flow.

Our study is limited in several respects. First, our measure of CVR is based on the percentage BOLD change per millimeter of mercury P\textsubscript{ET}CO\textsubscript{2}. The BOLD signal does not measure blood flow directly but represents an interaction of arterial partial pressure of oxygen, cerebral blood flow, cerebral blood volume, hematocrit, and cerebral metabolic rate of oxygen. However, we have previously shown that the BOLD MR imaging signal response to hypercapnia is well-correlated with CBF measurements obtained by using arterial spin-labeling in patients with steno-occlusive disease. Second, only a subset of subjects underwent quantitative T2 measurements (54 of 75 subjects) and perfusion measurements (25 of 75 subjects). Third, we report only limited cognitive measures; only the Montreal Cognitive Assessment score was collected, which did not provide a detailed profile of each subject’s cognitive status. In this respect, our study was not designed to assess the relationship between impaired CVR and cognitive function. An extensive neuropsychological battery would have been needed for this purpose. Finally, we acknowledge that the criterion standard of histopathologic diagnosis was not obtained in our patient cohort.

**CONCLUSIONS**

WMH demonstrate abnormal hemodynamic parameters in a pattern consistent with diminished blood flow regulation and increased vulnerability to transient ischemia compared with NAWM. It remains to be determined whether impaired CVR is a causative and/or predictive factor in the pathogenesis of leukoaraiosis versus a secondary response to the reduced metabolic activity of leukoaraiotic tissue. Whether the impaired reactivity in white matter precedes white matter tissue injury or vice versa remains unclear, and a 1-year follow-up study in this cohort of patients is planned to better address this question. Nevertheless, our findings support the hypothesis that vascular dysfunction in cerebrovascular regulation is an important factor in the pathophysiology of white matter disease.

### Table 2: Measurements of CVR, FA, MD, T2, and perfusion metrics in WMH and contralateral homologous NAWM

|                  | WMH (Contralateral to NAWM, Mean (SD)) | NAWM (Contralateral to WMH, Mean (SD)) | Paired Differences | t-Score | df |
|------------------|----------------------------------------|--------------------------------------|--------------------|--------|----|
| CVR (% BOLD/mm Hg) | 0.05 (0.07)                           | 0.13 (0.03)                          | 0.06 (0.03)        | 0.05–0.07 | 14.8* | 74 |
| FA (unitless)     | 0.28 (0.07)                           | 0.50 (0.11)                          | 0.18 (0.04)        | 1.72–1.91 | 38.2* | 74 |
| MD (×10\textsuperscript{-3} mm\textsuperscript{2}/s) | 1.37 (0.11)                           | 0.84 (0.03)                          | 0.51 (0.11)        | 0.48–0.54 | 40.7* | 74 |
| T2 (ms)          | 136.7 (14.4)                          | 84.9 (4.9)                           | 51.6 (11.8)        | 48.5–54.8 | 32.3* | 53 |
| CBF (mL/100 g/min)| 18.2 (3.5)                            | 21.0 (4.4)                           | 2.9 (4.3)          | 0.16–3.7   | 2.8 (P < .01) | 24 |
| rCBV (AU)\textsuperscript{b} | 103.9 (10.3)                        | 117.5 (9.3)                          | 8.9 (9.7)          | 0.8–17.7   | 2.3 (P = .03) | 24 |
| Tmax (s)         | 4.6 (0.5)                             | 4.1 (0.3)                            | 0.3 (1.1)          | −0.1–0.8   | 1.5 (P = .15) | 24 |
| MTT (s)          | 3.5 (0.3)                             | 2.4 (0.2)                            | 1.1 (0.8)          | 0.8–1.2    | 6.8*  | 24 |
| TTP (s)          | 22.3 (1.3)                            | 20.8 (1.0)                           | 1.6 (1.2)          | 1.1–2.1    | 6.7*  | 24 |

Note: FA indicates fractional anisotropy; rCBV, relative CBV; Tmax, time-to-maximum; AU, arbitrary units.

\textsuperscript{a} P < .001 compared with contralateral WMH.

\textsuperscript{b} These arbitrary units indicate that WMH are reduced compared to contralateral NAWM by 10.2%
ACKNOWLEDGMENTS

We are grateful to the Toronto Western Hospital and Sunnybrook Health Sciences Centre RespirAct technologists, Anne Battisti-Charbonneu and Diem Pham, and the MR imaging technologists, Keith Ta and Eugen Hlasny. We also thank David Crane (Mac-Intosh laboratory manager) and Anoop Ganda (psychometrist/research coordinator) for enabling the Sunnybrook data acquisition, which required availability after hours and on weekends. Last, we greatly appreciate the assistance of Alicia McNeely and Courtney Berezuk, Sunnybrook BrainLab imaging analysts, for identifying areas of white matter hyperintensities and lacunes for the Sunnybrook dataset, and to Christopher Scott, Sunnybrook BrainLab manager, for facilitating training and analysis by using the Lesion Explorer pipeline.

Disclosures: Kevin Sam—RELATED: Grant: Research funding was provided by the Canadian Stroke Network from 2010 to 2014. *Olivia Sobczyk—UNRELATED: Consultancy: Thornhill Research Inc. Comments: for the RespirAct device, but not in relation to the submitted work. James Duffin—UNRELATED: Employment: I am the senior scientist at Thornhill Research. Joseph A. Fisher—UNRELATED: Other: I am one of the inventors of the RespirAct used in the study. I also have shares in and sit on the board of the company. Thornhill Research is a spinoff from the University Health Network, part of the University of Toronto. The RespirAct is a research tool and not a commercial product. Should it ever become one, I would stand to profit. *OTHER: coinventor of the RespirAct, a device used in this study. I also hold shares and serve as a director of Thornhill Research Inc, a University of Toronto/University Health Network–related company, which retains an ownership position and will receive royalties should the RespirAct become a commercial product. Sandra E. Black—UNRELATED: Network–related company, which retains an ownership position and will receive royalties should the RespirAct become a commercial product. *OTHER: coinventor of the RespirAct, a device used in this study. I also hold shares and serve as a director of Thornhill Research Inc, a University of Toronto/University Health Network–related company, which retains an ownership position and will receive royalties should the RespirAct become a commercial product. Joseph A. Fisher—UNRELATED: Other: I am one of the inventors of the RespirAct used in the study. I also have shares in and sit on the board of the company. Thornhill Research is a spinoff from the University Health Network, part of the University of Toronto. The RespirAct is a research tool and not a commercial product. Should it ever become one, I would stand to profit. *OTHER: coinventor of the RespirAct, a device used in this study. I also hold shares and serve as a director of Thornhill Research Inc, a University of Toronto/University Health Network–related company, which retains an ownership position and will receive royalties should the RespirAct become a commercial product. Sandra E. Black—UNRELATED: Grant: Canadian Stroke Network (2010–2014). *UNRELATED: Grants/Grants Pending: Elan, *Roche, *GE Healthcare, *Eli Lilly, *Pfizer, *Lundbeck, *GlaxoSmithKline, *Transition Therapeutics, *Biogen Idec. *Comments: contract research to the institution; Payment for Lectures (including service on Speakers Bureau): Continuing Medical Education lectures for Novartis, Eisai, Pfizer; OTHER: received compensation in the past 2 years for ad hoc consulting with Boehringer Ingelheim and Novartis and honoraria from the Rehabilitation Institute of Chicago, the Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, Eisaie Korea, and Novartis. My research unit is receiving research funding from Roche, GE Healthcare, Lilly Avid, Pfizer, Lundbeck, and Transition Therapeutics. I also receive research funding from the Canadian Institutes of Health Research, National Institutes of Health, Heart and Stroke Foundation of Canada, Alzheimer Drug Discovery Foundation, Weston Foundation, Brain Canada, University of Toronto Department of Medicine, and the Ontario Brain Institute. David J. Mikulis—RELATED: Grant: Canadian Institutes of Health Research*, *UNRELATED: Canadian Institutes of Health Research*, *GE Healthcare*, *Physician’s Services Incorporation Corporation: Stock/Stock Options: stock (<2% equity in Thornhill Research Inc, the vendor of the RespirAct); OTHER: I am coinventor of the RespirAct, a device used in this study and hold a minor equity position in Thornhill Research Inc and have received research support from GE Healthcare, Siemens, Toshiba, and the Ontario Research Fund. *Money paid to the institution.

REFERENCES

1. Simpson JE, Fernando MS, Clark L, et al: MRC Cognitive Function and Ageing Neuropathology Study Group. White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses. *Neuropathol Appl Neurobiol* 2007;33:410–19 CrossRef Medline
2. Hachinski VC, Potter P, Merskey H. Leuko-araiosis: an ancient term for a new problem. Can J Neurol Sci 1986;13(4 suppl):533–34 Medline
3. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study—the Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001;70:9–14 CrossRef Medline
4. Launer LJ, Berger K, Breteler MM, et al. Regional variability in the prevalence of cerebral white matter lesions: an MRI study in 9 European countries (CASCADE), Neuroepidemiology 2006;26:23–29 Medline
5. Vredelhio A, Madureira S, Moleiro C, et al; LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. *Neurology* 2010;75:160–67 CrossRef Medline
6. Whitman GT, Tang Y, Lin A, et al. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. *Neurology* 2001;57:990–94 CrossRef Medline
7. Ogama N, Sakurai T, Shimizu A, et al. Regional white matter lesions predict falls in patients with amnestic mild cognitive impairment and Alzheimer’s disease. *J Am Med Dir Assoc* 2014;15:36–41 CrossRef Medline
8. Malmstrom TK, Morley JE. The frail brain. *J Am Med Dir Assoc* 2013;14:453–55 CrossRef Medline
9. Moody DM, Santamore WP, Bell MA. Does tortuosity in cerebral arteries impair down-autoregulation in hypertensives and elderly normotensives? A hypothesis and computer model. Clin Neurosurg 1991;37:372–87 Medline
10. Farkas E, de Vos RA, Donka G, et al. Age-related microvascular degeneration in the human cerebral periventricular white matter. Acta Neuropathol 2006;111:150–57 CrossRef Medline
11. Moody DM, Brown WR, Challa VR, et al. Periventricular venous collagenses: association with leukoaraiosis. Radiology 1995;194:469–76 CrossRef Medline
12. Moody DM, Brown WR, Challa VR, et al. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease. Ann N Y Acad Sci 1997;826:103–16 CrossRef Medline
13. Henry-Feugeas MC. Alzheimer’s disease in late-life dementia: a minor toxic consequence of devastating cerebrovascular dysfunction. Med Hypotheses 2008;70:866–75 CrossRef Medline
14. Mandell DM, Han JS, Poubilanc J, et al. Selective reduction of blood flow to white matter during hypercapnia corresponds with leukoaraiosis. Stroke 2008;39:1993–98 CrossRef Medline
15. Sachdev P, Wen W, Chen X, et al. Progression of white matter hyperintensities in elderly individuals over 3 years. Neurology 2007;68:214–22 CrossRef Medline
16. Fierstra J, Poubilanc J, Han JS, et al. Steal physiology is spatially associated with cortical thinning. J Neurol Neurosurg Psychiatry 2010;81:290–93 CrossRef Medline
17. Markus H, Cullinane M. Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion. *Brain* 2001;124(pt 3):457–67 CrossRef Medline
18. Baluanti C, Viticchi G, Falsetti L, et al. Cerebral hemodynamics and cognitive performance in bilateral asymptomatic carotid stenosis. *Neurology* 2012;79:1788–95 CrossRef Medline
19. Conklin J, Fierstra J, Crawley AP, et al. Impaired cerebrovascular reactivity with steal phenomenon is associated with increased diffusion in white matter of patients with Moyamoya disease. Stroke 2010;41:1610–16 CrossRef Medline
20. Helenius J, Soinne L, Salonen O, et al. Leukoaraiosis, ischemic stroke, and normal white matter on diffusion-weighted MRI. Stroke 2002;33:45–50 CrossRef Medline
21. Conklin J, Fierstra J, Crawley AP, et al. Mapping white matter diffusion and cerebrovascular reactivity in carotid occlusive disease. Neurology 2011;77:431–38 CrossRef Medline
22. Uh J, Yezhuvath U, Cheng Y, et al. In vivo vascular hallmarks of diffuse leukoaraiosis. *J Magn Reson Imaging* 2010;32:184–90 CrossRef Medline
23. Fazekas F, Kleinent R, Offenhuser H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683–89 CrossRef Medline
24. Nasreddine ZS, Phillips NA, Ward DE, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53:695–99 CrossRef Medline
25. Han JS, Mikulis DJ, Mardimec A, et al. Measurement of cerebrovascular reactivity in pediatric patients with cerebral vasculopathy using blood oxygen level-dependent MRI. *Stroke* 2011;42:1261–69 CrossRef Medline
26. Slessarev M, Han J, Mardimec A, et al. Prospective targeting and control of end-tidal CO2 and O2 concentrations. *J Physiol* 2007;581(pt 3):1207–19 CrossRef Medline
27. Vesely A, Sasano H, Volgyesi G, et al. MRI mapping of cerebrovascular reactivity using square wave changes in end-tidal PCO2. Magn Reson Med 2001;45:101–13 CrossRef Medline
28. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996; 29:162–73 CrossRef Medline
29. Poublanç J, Crawley AP, Sobiczyk O, et al. Measuring cerebrovascular reactivity: the dynamic response to a step hypercapnic stimulus. J Cereb Blood Flow Metab 2015;35:1746–56 CrossRef Medline
30. Miller AJ, Joseph PM. The use of power images to perform quantitative analysis on low SNR MR images. Magn Reson Imaging 1993; 11:1051–56 CrossRef Medline
31. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208–19 CrossRef Medline
32. Jenkinson M, Bannister P, Brady M, et al. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41 CrossRef Medline
33. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143–55 CrossRef Medline
34. Kosior JC, Frayne R. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143–55 CrossRef Medline
35. Smith MR, Lu H, Trochet S, et al. PerfusionTool: a software platform for investigating bolus-tracking perfusion imaging quantification strategies. J Magn Reson Imaging 2007;25:653–59 CrossRef Medline
36. Ramirez J, Scott CJ, McNeely AA, et al. Lesion Explorer: a video-guided, standardized protocol for accurate and reliable MRI-derived volumetrics in Alzheimer’s disease and normal elderly. J Vis Exp 2014;(86) doi: 10.3791/50887 CrossRef Medline
37. Ramirez J, Gibson E, Quaddus A, et al. Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage 2011;54:963–73 CrossRef Medline
38. Bastin ME, Clayden JD, Patti A, et al. Diffusion tensor and magnetization transfer MRI measurements of periventricular white matter hyperintensities in old age. Neurobiol Aging 2009;30:125–36 CrossRef Medline
39. Maniega SM, Valdés Hernández MC, Clayden JD, et al. White matter hyperintensities and normal-appearing white matter integrity in the aging brain. Neurobiol Aging 2015;36:909–18 CrossRef Medline
40. Feldman HM, Yeatman JD, Lee ES, et al. Diffusion tensor imaging: a review for pediatric researchers and clinicians. J Dev Behav Pediatr 2010;31:346–56 CrossRef Medline
41. Haller S, Kovari E, Herrmann FR, et al. Do brain T2/FLAIR white matter hyperintensities correspond to myelin loss in normal aging? A radiologic-neuropathologic correlation study. Acta Neuropathol Commun 2013;1:14 CrossRef Medline
42. Lin CY, Chang C, Cheung WM, et al. Dynamic changes in vascular permeability, cerebral blood volume, vascular density, and size after transient focal cerebral ischemia in rats: evaluation with contrast-enhanced magnetic resonance imaging. J Cereb Blood Flow Metab 2008;28:1491–501 CrossRef Medline
43. Sobiczyk O, Battisti-Charbonney A, Fierstra J, et al. A conceptual model for CO2-induced redistribution of cerebral blood flow with experimental confirmation using BOLD MRI. Neuroimage 2014;92:56–68 CrossRef Medline
44. Hassan A, Hunt BJ, O’Sullivan M, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003;126(pt 2):424–32 CrossRef Medline
45. Brickman AM, Zahra A, Muraskin J, et al. Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging. Psychiatry Res 2009;172:117–20 CrossRef Medline
46. Marstrand JR, Garde E, Rostrup E, et al. Cerebral perfusion and cerebrovascular reactivity are reduced in white matter hyperintensities. Stroke 2002;33:972–76 CrossRef Medline
47. O’Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002;59:321–26 CrossRef Medline
48. Holland CM, Smith EE, Csapo I, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke 2008;39:1127–33 CrossRef Medline
49. Campbell BC, Christensen S, Levi CR, et al. Cerebral blood flow is the optimal CT perfusion parameter for assessing infarct core. Stroke 2011;42:3435–40 CrossRef Medline
50. Leoni RF, Mazzetto-Betti KC, Silva AC, et al. Assessing cerebrovascular reactivity in carotid steno-occlusive disease using MRI BOLD and ASL techniques. Radiol Res Pract 2012;2012:268483 CrossRef Medline
51. Ogawa S, Lee TM, Barrere B. The sensitivity of magnetic resonance image signals of a rat brain to changes in the cerebral venous blood oxygenation. Magn Reson Med 1993;29:205–10 CrossRef Medline
52. Mandell DM, Han JS, Poublanç J, et al. Mapping cerebrovascular reactivity using blood oxygen level-dependent MRI in patients with arterial steno-occlusive disease: comparison with arterial spin labeling MRI. Stroke 2008;39:2021–28 CrossRef Medline